Immuron Limited · ASX:IMC
Immuron — 21st Virtual Investor Summit Microcap Event (November 2024)
16 slides from Immuron's conference presentation, Nov 22, 2024
Slide 1: Immuron CEO presentation to 21st Virtual Investor Summit Microcap Event
Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event Melbourne, Australia, November 22, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented early this morning at the 21st Virtual Investor Sum
Slide 2: Platform technology, IMM-124E and IMM-529 background
are orally active. Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits direc
Slide 3: References and forward-looking statements
References Connor P, Porter CK, Swierczewski B and Riddle MS. Diarrhea during military deployment: current concepts and future directions. Curr Opin Infect Dis. 25(5): 546-54; 2012. Hutton, M.L., Cunningham, B.A., Mackin, K.E. et al. Bovine antibodies targeting primary and recurrent Clostridium diff
Slide 4: Virtual Investor Summit Microcap Event
NASDAQ: IMRN ASX: IMC For personal use only Virtual Investor Summit Microcap Event Steven Lydeamore Chief Executive Officer 21 November 2024
Slide 5: Safe Harbor Statement
SAFE HARBOR STATEMENT C e r ta i n state m e n t s m a d e i n t h i s p re s e nta t i o n a re fo r wa rd - l o o k i n g state m e n t s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c tat i o n s , e st i m ate s a n d p ro j e c t i o n s . Wo rd s s u c h a s For personal use onl
Slide 6: Executive summary
Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases For personal use only Company Overview Financial Snapshot Two commercially available
Slide 7: Opportunity to Convert Billion Dollar Traveller's Diarrhoea Market from Relief to Prevention
Opportunity to Convert Billion Dollar Traveller’s Diarrhoea Market from Relief to Prevention by Travelan® Billion Dollar Market Traveller’s diarrhoea treatment market is large and growing at a CAGR of ~7%1 For personal use only Industry tailwinds International travel continues to grow Travel to high
Slide 8: Travelan continued strong sales growth
Travelan® continued strong sales growth Global For personal use only + Q1 FY2025 AUD$1.5 million up 13% on prior quarter Australia + Q1 2025 AUD$1.0 million up 3% on prior quarter + Secured core ranging in another nine pharmacy banner groups North America + Q1 2025 AUD$0.5 million up 48% on prior qu
Slide 9: Continued strong sales growth
CONTINUED STRONG SALES GROWTH For personal use only o Global sales increased by 172% in the 2024 fiscal year to a o USA record A$4.90 million compared to A$1.80 million in FY23 o FY24: a record A$1.08 million; up 67% o Record monthly sales in October 2024 of $1.49 million o Q1, FY25: A$0.28 million
Slide 10: Expansion of Travelan distribution
EXPANSION OF TRAVELAN® DISTRIBUTION For personal use only 7
Slide 11: Consumer marketing activity driving Travelan sales growth
CONSUMER MARKETING ACTIVITY DRIVING TRAVELAN® SALES GROWTH We continue to drive awareness, For personal use only consideration and engagement o Ranging across major retailers (Australia, Canada) o In-store positioning and promotion o Retailer catalogues o Search and social media marketing o Social c
Slide 12: World first triple mechanism of action for CDI
WORLD FIRST TRIPLE MECHANISM OF ACTION FOR CDI IMM-529: pre-IND filed with FDA July 2024; successful pre-IND meeting Indication / Target IMM-529 will be indicated for the treatment of recurrent C. difficile For personal use only Population infection Product • Novel antibody-containing therapeutic wh
Slide 13: Immuron's clinical programs – opportunity assessment
IMMURON’S CLINICAL PROGRAMS – OPPORTUNITY ASSESSMENT › Immuron’s development of IMM-124E (hyperimmune › Infectious disease experts reacted favorably to the IMM-529 For personal use only bovine colostrum) as a prescription medication has MOA, and its unique ability to target three elements of the the
Slide 14: Upcoming Milestones
Upcoming Milestones Revenue For personal use only + Continued quarter on quarter growth from growth drivers + Secured core ranging in another nine Australian pharmacy banner groups + Strongest monthly sales on amazon.com in September 2024 + Secured distribution in ten pharmacy/grocery retailers in C
Slide 15: Steven Lydeamore, Chief Executive Officer
For personal use only STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172
Slide 16: Scientific references
Scientific references Travelan® (IMM-124E) For personal use only Travelan® has been shown to reduce both the incidence and severity of ETEC- Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: 10.3109/00365521.2011.574726 induced diarrhea in up to 90% of volunteers Clinical Evaluation of
Immuron — 21st Virtual Investor Summit Microcap Event (November 2024) on 6ix